Patient-Derived Xenograft (PDX) models have emerged as invaluable tools in preclinical cancer research, providing a bridge between traditional in vitro studies and human clinical trials. These models involve implanting patient tumor samples directly into immunodeficient mice, allowing researchers to study tumor behavior, response to treatments, and potential therapeutic strategies in a more clinically relevant setting.
Emulate Inc. partners with MD Anderson Cancer Center to develop advanced PDX models for personalized medicine: This collaboration combines Emulate's Organ-on-a-Chip technology with MD Anderson's expertise in PDX models to create personalized tumor microenvironments for drug testing and treatment response prediction.
Charles River Laboratories acquires Oncodesign, expanding its global PDX capabilities: This acquisition strengthens Charles River's position as a leading provider of PDX models and related services, offering broader access to diverse tumor types and expertise.
XenTech and Transgene announce a strategic partnership to develop and commercialize novel PDX models for immuno-oncology research: This collaboration harnesses XenTech's humanized mouse immune system platform with Transgene's extensive PDX library to create models that accurately predict the efficacy of immuno-oncology drugs.
Charles River Laboratories
The Jackson Laboratory
Crown Bioscience
Altogen Labs
Envigo
WuXi AppTec
Oncodesign
Hera Biolabs
XenTech
Abnova Corp.
Patient Derived Xenograft Model Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)